Literature DB >> 21575745

Systemic sclerosis refractory disease: from the skin to the heart.

Isabel Almeida1, Raquel Faria, Pedro Vita, Carlos Vasconcelos.   

Abstract

Systemic sclerosis or scleroderma (SSc) is an heterogeneous disease involving the connective tissue and the microvasculature with fibrosis and vascular occlusion. It is difficult to define refractory SSc once it is itself a paradigm of a refractory condition: there is no evidence of when to act to stop the progression to fibrosis and irreversible microvascular damage. There is no definition of refractory disease in SSc and to propose a definition we used mainly the Medsger severity index and the EULAR 2009 treatment recommendations from the skin to the heart through peripheral vascular, musculoskeletal, gastrointestinal, renal, pulmonary hypertension and interstitial lung disease. We used some clinical setting reflecting the different reasoning when there is probable refractory disease and finally we briefly pointed out some available treatment options to refractory disease. With this reflection, we would like to open paths to a broader discussion.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575745     DOI: 10.1016/j.autrev.2011.04.025

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  14 in total

1.  An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model.

Authors:  Tetsuya Nishimoto; Logan Mlakar; Takahisa Takihara; Carol Feghali-Bostwick
Journal:  Int Immunopharmacol       Date:  2015-08-24       Impact factor: 4.932

Review 2.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

Review 3.  Autoimmunity in 2011.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

4.  RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.

Authors:  Chenming Sun; Shi-You Chen
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

5.  Elevated serum levels of soluble CD146 in patients with systemic sclerosis.

Authors:  Tomoko Ito; Naoto Tamura; Sayuri Okuda; Kurisu Tada; Masakazu Matsushita; Ken Yamaji; Kazunori Kato; Yoshinari Takasaki
Journal:  Clin Rheumatol       Date:  2016-10-11       Impact factor: 2.980

Review 6.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 7.  Dupuytren's: a systems biology disease.

Authors:  Samrina Rehman; Royston Goodacre; Philip J Day; Ardeshir Bayat; Hans V Westerhoff
Journal:  Arthritis Res Ther       Date:  2011-09-12       Impact factor: 5.156

8.  Optimization of a murine and human tissue model to recapitulate dermal and pulmonary features of systemic sclerosis.

Authors:  Tomoya Watanabe; Tetsuya Nishimoto; Logan Mlakar; Jonathan Heywood; Maya Malaab; Stanley Hoffman; Carol Feghali-Bostwick
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

Review 9.  Serotonin paracrine signaling in tissue fibrosis.

Authors:  Derek A Mann; Fiona Oakley
Journal:  Biochim Biophys Acta       Date:  2012-09-29

10.  Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis.

Authors:  Xinh-Xinh Nguyen; Tetsuya Nishimoto; Takahisa Takihara; Logan Mlakar; Amy D Bradshaw; Carol Feghali-Bostwick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-10-07       Impact factor: 6.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.